Lien T Nguyen

US Patent:

54096170, Apr 25, 1995

Filed:

Jul 13, 1993

Appl. No.:

8/091617

Inventors:

David S. Ross - Palo Alto CA
Indira Jayaweera - Fremont CA
Lien Nguyen - San Jose CA
Georgina P. Hum - Menlo Park CA
Werner R. Haag - San Jose CA

Assignee:

SRI International - Menlo Park CA

International Classification:

C02F 102
C02F 172

US Classification:

210762

Abstract:

The present invention relates to a process for the disposal of waste or the conversion of hydrothermally labile chemical groups and compounds to species which are environmentally acceptable, or are amendable to further degradation by conventional disposal systems to produce environmentally acceptable products, which process comprises: (a) conveying an aqueous solution or slurry of ordnance waste material into a reaction zone capable of withstanding the temperatures and pressures of hydrothermal decomposition; (b) reacting the waste material in the reaction zone with an aqueous composition comprising one or more alkali or alkaline earth metal silicates, borates, phosphates, biphosphates, or trisubstituted-phosphates, at between 200. degree. C. and 500. degree. C. and at a pressure between 10 and 400 atmospheres for between about 0. 01 and 10 minutes; (c) producing compounds which are environmentally acceptable or are amenable to further degradation by conventional disposal systems; and (d) optionally degrading further the compounds of step (e) by reaction in a conventional disposal system.

US Patent:

20230031009, Feb 2, 2023

Filed:

Feb 11, 2021

Appl. No.:

17/801486

Inventors:

- NEW HAVEN CT, US
Lien Nguyen - Jamaica Plain MA, US

International Classification:

A61K 31/4741
A61K 31/337
A61K 31/437
A61K 31/675
A61K 31/704
A61P 25/28
A61K 33/14

Abstract:

The present invention is directed to a method of treatment, including prevention or reducing the likelihood of adverse effects of chemotherapy comprising reducing and/or inhibiting chemotherapy-induced adverse effects (CIAE), especially central nervous system adverse effects, such as cognitive effects (especially chemotherapy induced cognitive impairment or CICI, also referred to as reduced cognition, cognitive impairment or chemobrain) by administering to the patient in need, including co-administering to the subject in need a pharmaceutically effective amount of a protein kinase C (PKC, often, PKC α and/or β) inhibitor, alone or in combination with a lithium salt. Related pharmaceutical compositions are also provided by the present invention.